Literature DB >> 32133741

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Burkert Pieske1,2,3,4, Carsten Tschöpe1,2,5, Rudolf A de Boer6, Alan G Fraser7, Stefan D Anker1,2,5,8, Erwan Donal9, Frank Edelmann1,2, Michael Fu10, Marco Guazzi11,12, Carolyn S P Lam13,14, Patrizio Lancellotti15, Vojtech Melenovsky16, Daniel A Morris1, Eike Nagel17,18, Elisabeth Pieske-Kraigher1, Piotr Ponikowski19, Scott D Solomon20, Ramachandran S Vasan21, Frans H Rutten22, Adriaan A Voors6, Frank Ruschitzka23, Walter J Paulus24, Petar Seferovic25, Gerasimos Filippatos26,27.   

Abstract

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for heart failure symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular (LV) ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), LV filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1 : Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2 : Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.
© 2020 European Society of Cardiology.

Entities:  

Keywords:  Biomarkers; Diagnosis; Echocardiography; Exercise echocardiography; HFpEF; Heart failure; Natriuretic peptides

Mesh:

Year:  2020        PMID: 32133741     DOI: 10.1002/ejhf.1741

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  48 in total

1.  Plasma biomarkers outperform echocardiographic measurements for cardiovascular risk prediction in kidney transplant recipients: results of the HOME ALONE study.

Authors:  Insa E Emrich; Anja L Scheuer; Kyrill S Rogacev; Felix Mahfoud; Stefan Wagenpfeil; Danilo Fliser; Stephan H Schirmer; Michael Böhm; Gunnar H Heine
Journal:  Clin Kidney J       Date:  2021-10-28

Review 2.  Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

Authors:  Joanna M Bilak; Uazman Alam; Christopher A Miller; Gerry P McCann; Jayanth R Arnold; Prathap Kanagala
Journal:  Card Fail Rev       Date:  2022-07-01

Review 3.  The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics.

Authors:  Frank R Heinzel; Sanjiv J Shah
Journal:  Herz       Date:  2022-06-29       Impact factor: 1.740

4.  Emerging Topics Update of the Brazilian Heart Failure Guideline - 2021.

Authors:  Fabiana G Marcondes-Braga; Lídia Ana Zytynski Moura; Victor Sarli Issa; Jefferson Luis Vieira; Luis Eduardo Rohde; Marcus Vinícius Simões; Miguel Morita Fernandes-Silva; Salvador Rassi; Silvia Marinho Martins Alves; Denilson Campos de Albuquerque; Dirceu Rodrigues de Almeida; Edimar Alcides Bocchi; Felix José Alvarez Ramires; Fernando Bacal; João Manoel Rossi Neto; Luiz Claudio Danzmann; Marcelo Westerlund Montera; Mucio Tavares de Oliveira Junior; Nadine Clausell; Odilson Marcos Silvestre; Reinaldo Bulgarelli Bestetti; Sabrina Bernadez-Pereira; Aguinaldo F Freitas; Andréia Biolo; Antonio Carlos Pereira Barretto; Antônio José Lagoeiro Jorge; Bruno Biselli; Carlos Eduardo Lucena Montenegro; Edval Gomes Dos Santos Júnior; Estêvão Lanna Figueiredo; Fábio Fernandes; Fabio Serra Silveira; Fernando Antibas Atik; Flávio de Souza Brito; Germano Emílio Conceição Souza; Gustavo Calado de Aguiar Ribeiro; Humberto Villacorta; João David de Souza Neto; Livia Adams Goldraich; Luís Beck-da-Silva; Manoel Fernandes Canesin; Marcelo Imbroinise Bittencourt; Marcely Gimenes Bonatto; Maria da Consolação Vieira Moreira; Mônica Samuel Avila; Otavio Rizzi Coelho Filho; Pedro Vellosa Schwartzmann; Ricardo Mourilhe-Rocha; Sandrigo Mangini; Silvia Moreira Ayub Ferreira; José Albuquerque de Figueiredo Neto; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

Review 5.  Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.

Authors:  Nazha Hamdani; Sarah Costantino; Andreas Mügge; Djamel Lebeche; Carsten Tschöpe; Thomas Thum; Francesco Paneni
Journal:  Eur Heart J       Date:  2021-05-21       Impact factor: 29.983

6.  Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score.

Authors:  Olivier Huttin; Alan G Fraser; Lars H Lund; Erwan Donal; Cecilia Linde; Masatake Kobayashi; Tamas Erdei; Jean-Loup Machu; Kevin Duarte; Patrick Rossignol; Walter Paulus; Faiez Zannad; Nicolas Girerd
Journal:  ESC Heart Fail       Date:  2021-03-03

7.  Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction.

Authors:  Yoshiharu Kinugasa; Kensuke Nakamura; Hiroko Kamitani; Masayuki Hirai; Kiyotaka Yanagihara; Masahiko Kato; Kazuhiro Yamamoto
Journal:  ESC Heart Fail       Date:  2021-03-18

8.  Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.

Authors:  Sara Hadzibegovic; Alessia Lena; Timothy W Churchill; Jennifer E Ho; Sophia Potthoff; Corinna Denecke; Lukas Rösnick; Katrin Moira Heim; Malte Kleinschmidt; Leif Erik Sander; Martin Witzenrath; Norbert Suttorp; Alexander Krannich; Jan Porthun; Tim Friede; Javed Butler; Ursula Wilkenshoff; Burkert Pieske; Ulf Landmesser; Stefan D Anker; Gregory D Lewis; Carsten Tschöpe; Markus S Anker
Journal:  Eur J Heart Fail       Date:  2021-07-12       Impact factor: 17.349

9.  Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.

Authors:  Virginia S Hahn; Hildur Knutsdottir; Xin Luo; Kenneth Bedi; Kenneth B Margulies; Saptarsi M Haldar; Marina Stolina; Jun Yin; Aarif Y Khakoo; Joban Vaishnav; Joel S Bader; David A Kass; Kavita Sharma
Journal:  Circulation       Date:  2020-10-29       Impact factor: 29.690

Review 10.  Salivary Biomarkers for Diagnosis and Therapy Monitoring in Patients with Heart Failure. A Systematic Review.

Authors:  Aidonis Rammos; Aris Bechlioulis; Petros Kalogeras; Evanthia E Tripoliti; Yorgos Goletsis; Anna Kalivi; Effrosyni Blathra; Pietro Salvo; M Giovanna Trivella; Tommaso Lomonaco; Roger Fuoco; Francesca Bellagambi; Chris J Watson; Abdelhamid Errachid; Dimitrios I Fotiadis; Lampros K Michalis; Katerina K Naka
Journal:  Diagnostics (Basel)       Date:  2021-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.